RE: Today's news...Is this comment by Dr. Seymour a friendly reminder to Big Pharma to step up the pace on whateverthefarktheyaredoing with their EKC-Cide testing?
"These results confirm that our EKC-Cide is likely the best available drug candidate in development against EKC," said Eugene Seymour, MD, MPH, CEO of the Company, adding, "We are now planning to evaluate its effect against herpes virus infection of the external eye."
Together, herpesviruses and adenoviruses are the principal causes of serious viral diseases of the external eye. At present, there is no satisfactory treatment for adenoviral keratitis/conjunctivitis. The potential domestic market for an effective drug against all viral infections of the external eye is variously estimated to be from $500M to billions of dollars.
Market Data 
Markets 
AI
